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Summary
Glioblastomas (World Health Organisation (WHO) grade
IV) and anaplastic gliomas (astrocytomas, oligoastrocyt-
omas, oligodendrogliomas) (WHO grade III) are collect-
ively referred to as malignant gliomas. The diagnosis of
malignant glioma may be suspected based on clinical his-
tory and neuroimaging findings, but histological confirm-
ation remains the diagnostic “gold standard”. Molecular
markers such as 1p/19q codeletion and isocitrate dehydro-
genase (IDH) mutation provide important diagnostic and
prognostic information. O–methylguanylmethyltransferase
(MGMT) promoter methylation is another favourable pro-
gnostic marker and predicts benefit from alkylating agent
chemotherapy in glioblastoma. Additionally, the extent of
neurosurgical resection is a prognostic factor. Radiotherapy
of the involved brain region or chemotherapy using the al-
kylating agent, temozolomide, are common therapeutic op-
tions for patients with anaplastic glioma. In contrast, te-
mozolomide plus radiotherapy is the standard of care for
most patients with glioblastoma. The increasing population
of elderly patients with glioblastoma represents a particular
challenge, with surgery followed by radiotherapy as the
standard of care. Contemporary clinical studies focus on
the role of angiogenesis. Specifically, pivotal phase III
studies exploring the antibody to vascular endothelial
growth factor (VEGF), bevacizumab, and the αvβ3/5 antag-
onist, cilengitide, in the management of newly diagnosed
glioblastoma have completed enrolment. Moreover, a
broad spectrum of other experimental treatment ap-
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proaches, including immunotherapy with vaccines against
glioma-associated antigens, are currently being explored in
phase I/II clinical trials.
Key words: glioblastoma; glioma chemotherapy;
radiotherapy; temozolomide
Epidemiology and clinical presentation
The diagnosis and grading of primary brain tumours fol-
lows the World Health Organisation (WHO) classification
[1]. The overall annual incidence of gliomas is in the range
of 5–6/100,000 (www.cbtrus.org) (table 1). Anaplastic as-
trocytomas, anaplastic oligoastrocytomas and anaplastic
oligodendrogliomas (WHO grade III), as well as glio-
blastomas (WHO grade IV), are collectively referred to
as malignant gliomas, whereas WHO grade I and II glio-
mas are designated low-grade gliomas. Among the ma-
lignant gliomas, anaplastic gliomas have a much better
prognosis than glioblastomas, and among the anaplastic
gliomas the detection of an oligodendroglial component
confers a better prognosis. Accordingly, for the definition
of more homogenous populations, these tumours are no
longer enrolled into the same clinical trials. The aetiology
of most malignant gliomas remains unknown. Some hered-
itary syndromes are associated with an increased glioma
risk, including Li-Fraumeni syndrome and neur-
ofibromatosis types I and II. Moreover, exposure to irradi-
ation in childhood has been linked to an increased risk for
glioma development.
At the present time, screening for gliomas has no clinical
relevance. This is because of the low incidence, the lack
of sensitive biomarkers in plasma, and the observation that
gliomas may develop apparently de novo within few weeks
or months. Thus, the diagnosis is mainly based on
neuroimaging in individuals suspected of harbouring an in-
tracranial lesion which is performed because of clinical
history (e.g. seizure, personality change or neurological
deficits) confirmed by neurological examination or enceph-
alography (EEG). Magnetic resonance imaging (MRI) is
the method of choice to rule out or detect an intracranial
neoplasm (figure 1). The diagnosis, treatment and follow-
up of patients with malignant gliomas is an interdisciplin-
ary challenge that is best met by specialised centres with
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dedicated brain tumour boards and interdisciplinary outpa-
tient clinics.
Histology and molecular pathology
All lesions suggestive of primary brain tumours should be
biopsied before therapeutic decisions are made. This in-
cludes elderly patients with large tumours for which no fur-
ther treatment may be a reasonable strategy. The rationale
for recommending a histological verification in all patients
includes the risk of false diagnoses made by neuroima-
ging alone. Obtaining a definitive tissue diagnosis is im-
portant to reassure physicians, patients and relatives, even
in situations where radiotherapy or chemotherapy are not
considered viable options. The diagnosis of an anaplastic
glioma (WHO grade III) as opposed to a grade II lesion is
based on mitotic activity in the context of a glial neoplasm.
Vascular proliferation and necrosis are important features
that define WHO grade IV tumours (glioblastomas). The
differentiation of mixed oligoastrocytomas from either
pure astrocytomas or pure oligodendrogliomas has re-
mained controversial [1] (figure 2).
Currently, at least three molecular markers assume an im-
portant diagnostic, prognostic or predictive role in malig-
nant gliomas [2] (figure 3): 1p/19q codeletion, MGMT pro-
moter methylation and IDH-1/2 mutation. The combined
loss of genetic material from chromosomes 1 and 19 is
probably caused by unstable translocations and is tightly
linked to gliomas with an oligodendroglial morphology [3,
4]. The 1p/19q codeletion is detected by fluorescent in
situ hybridisation or microsatellite-polymerase chain reac-
tion (PCR)-based assays for the detection of allelic losses,
and confers a more favourable prognosis. MGMT promoter
methylation is assessed by methylation-specific PCR of the
promoter region and is thought to result in loss of MGMT
protein, a DNA repair enzyme that counteracts alkylator-
induced DNA damage. This molecular marker is not dif-
ferentially distributed among various types of glioma, but
stands out as a putative predictive marker for benefit from
chemotherapy [5]. Mutations in the IDH genes, mainly
IDH-1, can be detected by PCR and direct sequencing, and
are very common in grade II and III gliomas but rare in
glioblastomas [6, 7]. This indicates that most glioblastomas
Figure 1
MRI features of right fronto-temporal glioblastoma: T2–weighted
MRI (left), T1–weighted MRI with contrast enhancement (middle)
and amino acid (18F-ethyltyrosine) PET overlay (right) (courtesy: F.
Kuhn, Zurich). On the left, a multifocal, irregular lesion with
prominent oedema and mass effect on the lateral ventricle is
depicted. In the middle, rim-like contrast enhancement around the
necrotic core tumour lesion can be observed. On the right, the PET
signal reflects hyper-metabolic areas around this necrotic lesion.
are biologically distinct tumours that are not related to typ-
ical lower grade precursor lesions [8]. The pathogenetic
role of IDH mutations in gliomagenesis remains contro-
versial, but may involve an altered, novel gain of function
of mutant IDH enzymes which produce an oncometabolite,
α-hydroxyglutarate. IDH mutations are prognostically fa-
vourable and almost never occur in elderly patients with
malignant gliomas, partially explaining the negative pro-
gnostic impact of age in these patients [7]. Finally, specific
antibodies to mutant IDHR132H have become a valuable dia-
gnostic tool because such mutations are very common in
grade II/III gliomas but absent, for example, in pilocytic as-
trocytomas or ependymomas [8].
Treatment of anaplastic glioma
Newly diagnosed disease
The classical treatment of newly diagnosed anaplastic
glioma includes resection to the extent feasible, followed
by radiotherapy (54–60 Gy in 1.8–2 Gy fractions) to the
tumour region with a safety margin of 2–3 cm, depending
on tumour location. Surgery in malignant glioma patients
commonly aims at removing as much of the tumour as pos-
sible, without causing new neurological deficits. Biopsy
may be the only option for multifocal tumours or tumours
involving the corpus callosum. The role of chemotherapy
in addition to radiotherapy has been addressed in various
studies, but the results are inconclusive. In the past, ana-
plastic astrocytoma patients were included in the same tri-
als as glioblastoma patients and the trials were not designed
to confirm an advantage of combined modality treatment
over radiotherapy alone. For instance, a large British trial
examined combined procarbacin, CCNU (lomustin) and
vincristin (PCV), albeit in an uncommon dosing regimen,
and reported a median survival of 15 months with radio-
therapy plus PCV versus 13 months with radiotherapy
alone [9]. Based on several smaller studies in the 1990’s,
with PCV given at recurrence after radiotherapy, both the
European Organisation for Research and Treatment of Can-
cer (EORTC) and the Radiation Therapy Oncology Group
(RTOG) in the USA and Canada explored the role of PCV
either prior to radiotherapy (EORTC 26951) or after radio-
therapy (RTOG 94–02) in anaplastic oligodendroglial tu-
mours. Both studies showed that the addition of PCV to ra-
diotherapy in newly diagnosed anaplastic oligodendroglial
tumours prolonged progression-free survival, but not over-
all survival [10, 11]. Since the haematological toxicity from
PCV was substantial, it was felt that adjuvant PCV should
not be considered the standard of care for these tumours.
As an alternative to intensive treatment in the newly dia-
gnosed setting, the German Neuro-Oncology Group
(NOA) explored whether chemotherapy using PCV or te-
mozolomide alone could substitute for radiotherapy alone
in the treatment of newly diagnosed anaplastic glioma. The
NOA-04 trial demonstrated no difference for progression-
free or overall survival between these first-line treatments
in anaplastic astrocytoma, oligoastrocytoma and oligo-
dendroglioma. Of note, temozolomide was as effective as
PCV, but better tolerated. Importantly, the median survival
exceeded 70 months, which was favourable compared with
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historical databases. Most likely, this survival advantage
indicates improved overall patterns of care rather than pa-
tient selection, given that 318 patients from many sites
across Germany were enrolled in this trial [12]. NOA-04
also demonstrated, for the first time in a prospective man-
ner, that anaplastic oligodendroglial tumours have a better
prognosis than anaplastic pure astrocytic gliomas. Oligo-
dendroglial and oligoastrocytic tumours shared the same
more favourable course. Accordingly, the current recom-
mendation for the management of anaplastic glioma pa-
tients is to use either radiotherapy or chemotherapy alone,
but not combined modality treatment (table 2).
Analyses of the three randomised trials [10–12] established
the prominent prognostic role of molecular markers in pa-
tients with anaplastic gliomas and revealed the following
findings: the 1p/19q codeletion is strongly associated with
oligodendroglial morphology and better outcome with
either radiotherapy alone, chemotherapy alone or com-
bined modality treatment [10–12]; MGMT promoter
methylation predicts longer progression-free and overall
survival independent of the type of genotoxic treatment
[12, 13]; and IDH mutations are common in all types of
anaplastic glioma and prognostically favourable independ-
ent of treatment, too [12, 14]. Accordingly, none of these
markers is presently useful for choosing between radiother-
apy, chemotherapy or combined modality treatment today
[2].
Recurrent disease
The failure of adjuvant PCV added to radiotherapy to in-
crease overall survival may result from the efficacy of the
treatment for recurrent disease (e.g. PCV or temozolomide
or both) when given as a salvage treatment at recurrence
after radiotherapy. In fact, several treatment options are
now available for patients with recurrent anaplastic glioma
(table 2). The choice is mainly determined by the type of
primary treatment, that means patients who have not been
previously irradiated should receive radiotherapy at recur-
rence. Patients irradiated at diagnosis should receive al-
kylating agent chemotherapy, and considering the favour-
able safety and tolerability profile, this should mostly be
temozolomide. Patients progressing after radiotherapy and
one or two lines of alkylating agent chemotherapy may be
treated with bevacizumab monotherapy [15, 16] or another
experimental treatment strategy.
Current trials
The cooperative trial groups have agreed that future studies
should take the difficulties in sub-classifying anaplastic
gliomas by morphology alone into consideration, as well as
the profound prognostic impact of molecular markers. Ac-
cordingly, the CATNON trial, in a 2x2 design, only enrols
patients with anaplastic glioma without 1p/19q codeletion
and examines the role of temozolomide added to radiother-
apy. The CATNON arms include radiotherapy alone, radio-
therapy plus concurrent temozolomide, radiotherapy plus
adjuvant temozolomide, and radiotherapy plus concomit-
ant and adjuvant temozolomide. Patients will be stratified
for MGMT promoter methylation status. A companion pro-
tocol, CODEL, for 1p/19q-codeleted tumours will compare
radiotherapy alone, chemotherapy alone and radiochemo-
therapy using temozolomide. This trial will thus combine
features of NOA-04 [12] and the EORTC NCIC trial for
glioblastoma (see below) [17].
Treatment of glioblastoma
Newly diagnosed disease
The standard of care for newly diagnosed glioblastoma in-
cludes surgical resection when feasible and involved-field
radiotherapy to 54–60 Gy in 1.8–2 Gy fractions, similar to
anaplastic glioma. The role of resection was confirmed by
demonstrating that the increase in the rate of complete re-
sections, aided by the fluorescent marker 5–aminolevulinic
acid to delineate the tumour area under the surgical micro-
scope, translated into improved progression-free survival at
6 months [18]. Although the impact of this trial has been
challenged because the adjuvant treatment consisted of ra-
diotherapy alone, and not radiotherapy plus temozolomide,
Table 1: Malignant gliomas: epidemiology and outcome (www.cbtrus.org).
Annual incidence per 100,000 Survival at 1 year (%) Survival at 3 years (%) Survival at 5 years (%)
Anaplastic astrocytoma 0.41 60.3 34.7 27.4
Anaplastic oligodendroglioma 0.12 79.9 59.6 49.4
Glioblastoma 3.19 34.6 7.3 4.8
Table 2: Current treatment options for malignant glioma patients.
Newly diagnosed Recurrence or progression
Anaplastic astrocytoma WHO grade III Resection (or biopsy) and radiotherapy or
temozolomidea,b (or radiotherapy plus
temozolomidec)
(Re-resection and) temozolomide or radiotherapy (or re-
irradiation) or bevacizumab
Anaplastic oligodendroglioma and anaplastic
oligoastrocytoma WHO grade III
Resection or biopsy and radiotherapy or
temozolomidea,b (or radiotherapy plus
temozolomidec)
(Re-resection and) temozolomide or radiotherapy (or re-
irradiation) or bevacizumab
Glioblastoma WHO grade IV Resectiond (or biopsy) and radiotherapy and
chemotherapy (temozolomide)e
(Re-resection and) chemotherapy (dose-intense
temozolomide or nitrosourea) (or re-irradiation) or
bevacizumabf
aNOA-04 trial [12]
bTemozolomide probably equieffective to nitrosoureas but better tolerated [12]
cexplored in the CATNON and CODEL trials
dStummer et al. [18]
eEORTC 26981–22981 NCIC CE.3 [17, 19]
fFriedman et al. [33], Kreisl et al. [34]
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which is the current standard of care [17], there is now little
doubt that the extent of resection determines progression-
free survival, degree of steroid dependence and, therefore,
quality of life.
Glioblastoma patients aged 70 or less with a good perform-
ance status should be treated with radiotherapy and con-
comitant and adjuvant temozolomide [17, 19]. The benefit
from chemotherapy is more prominent in younger patients,
in particular, in patients with MGMT promoter methylation
[19, 20]. Overall, there was an increase in median survival
from 12.1 to 14.6 months, and of the 2 year survival rate
Figure 2
Morphological characteristics of malignant gliomas: A = anaplastic
astrocytoma, B = anaplastic oligodendroglioma, C = glioblastoma
(for details, see text) (courtesy: E. Rushing, Zurich). A shows a
moderately cellular astrocytic tumour with mitoses and pleomorphic
nuclei. B shows closely apposed tumour cells with round nuclei and
perinuclear halos accompanied by mitoses typical of an anaplastic
oligodendroglioma. C shows areas of necrosis and perinecrotic
palisade formation characteristic of glioblastoma.
from 11% to 27% in patients receiving temozolomide, and
the 2 year survival rate approached 49% in temozolomide-
treated patients with MGMT promoter methylation [19].
Since the introduction of temozolomide, the role of nitro-
soureas given either systemically or locally in the form of
wafers [21] has steadily declined.
The standard of care for the large population of elderly pa-
tients with glioblastoma is less well defined. Radiotherapy
is superior to best supportive care [22] and can be admin-
istered in an accelerated fashion (40 Gy in 15 fractions)
[23]. Whether temozolomide alone is equally effective as
radiotherapy remains controversial. The preliminary report
Figure 3
Molecular markers in malignant glioma. A: 1p/19q codeletion.
Microsatellite-PCR-based analysis of allelic losses of 1p and 19q in
an astrocytoma (WHO grade II) (A II) and an anaplastic
oligodendroglioma (WHO grade III) (AO III). Losses of both markers
are indicated by arrowheads in AO III, but not A II. B: MGMT
promoter methylation. Methylation-specific PCR for unmethylated
(U) and methylated (M) promoter sequences in 5 glioblastoma
samples, including the glioblastoma cell line A172 as a positive
control for methylated and peripheral blood cells as a control for
unmethylated promoter sequences, as well as water as a negative
control. C: IDH mutation. Grade II oligoastrocytoma, upper panels:
HE staining, lower panels: IDH immunostaining, left panels: tumour
centre, right panels: infiltration zone (Courtesy: J. Felsberg,
Düsseldorf).
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from the Nordic trial reported no difference [24], where-
as the preliminary report from the NOA-08 trial failed
to demonstrate non-inferiority of dose-dense TMZ alone
versus radiotherapy alone [25]. A large prospective study
of elderly glioblastoma patients from the German Glioma
Network identified a strong predictive value of MGMT pro-
moter methylation for benefit from temozolomide. Accord-
ingly, the results from the Nordic trial and NOA-08 may
only be adequately interpreted when data on the relation-
ship between MGMT promoter methylation status and out-
come become available [26].
Recurrent disease
Therapeutic options for patients with recurrent glio-
blastoma are steadily increasing, but standards of care are
not well defined. A minority of patients, approximately
20–25%, may benefit from a second surgery and some pa-
tients are candidates for a second course of radiotherapy.
Whether these are good options depends on the site and
pattern of relapse as well as the interval from the prior
treatment. Randomised trials seeking to prove the role of
novel agents including the tyrosine kinase inhibitor, er-
lotinib [27], the protein kinase C-β inhibitor, enzastaurin
[28], or the VEGF receptor inhibitor, cediranib [29], which
were all negative, confirmed the limited activity of nitro-
soureas in temozolomide-pretreated glioblastoma patients.
Moreover, there is ongoing interest in determining the best
mode of administration of a temozolomide “rechallenge”
in this patient population. In fact, progression-free survival
rates of 30% at 6 months may be expected using one of sev-
eral dose-intensified temozolomide regimens [30, 31]. In-
terestingly, a British trial in recurrent, temozolomide-naïve
malignant glioma patients failed to confirm a superiority of
a dose-intensified over conventionally-dosed temozolom-
ide regimen [32].
Bevacizumab has been approved for the treatment of re-
current glioblastoma in various countries including USA
and Switzerland, but not in the European Union. The ap-
proval was based on two prospective trials that reported ra-
diological response rates of 30% or more and promising
progression-free and overall survival times, but did not in-
clude a bevacizumab-free control arm [33, 34]. The value
of bevacizumab in the management of malignant gliomas
is universally accepted, but many questions remain regard-
ing timing and dosing schedules.
Current trials
Results from the largest glioblastoma trial ever performed,
RTOG 0525, on dose-intensified temozolomide in newly
diagnosed glioblastoma will be presented at the ASCO
meeting in June 2011. Based on promising phase II data,
two inhibitors of angiogenesis, bevacizumab [35] and ci-
lengitide [36], have been evaluated in phase III registration
trials in patients with newly diagnosed glioblastoma. The
AVAGlio trial administered bevacizumab to all glio-
blastoma patients, whereas the CENTRIC trial on cilen-
gitide restricted inclusion to resected patients with MGMT
promoter methylation, based on the preferential benefit
seen in this patient population in the phase II trial [36].
Both trials have completed enrolment, but results will not
be available for some time. Meanwhile, there is renewed
interest in immunotherapy with a randomised vaccination
trial for glioblastoma patients carrying a specific mutation
of the epidermal growth factor receptor (EGFR), EGFRvIII
[37]. Whether a large trial using this complex treatment
approach will be feasible is unclear at present. Moreover,
there are many novel agents which are presently being ex-
plored in exploratory, mostly phase I/II trials in the recur-
rent setting.
Monitoring treatment response and
course of disease
Neuroimaging is the primary monitoring tool for brain tu-
mour patients, with MRI as the method of choice. MRI
is usually done in 2–3 month intervals during treatment,
but intervals can be prolonged during longer treatment-
and disease progression-free periods, notably in patients
with anaplastic gliomas. The introduction of anti-angiogen-
ic agents into the management of malignant gliomas has
necessitated a revision of the traditional criteria [38], which
relied heavily on contrast enhancement. Since contrast en-
hancement is mediated in part by VEGF, accordingly the
efficacy of VEGF antagonists will be overestimated by cri-
teria that do not consider T2–weighted and fluid-attenuated
inversion recovery (FLAIR) sequences [39].
Pseudoprogression refers to an apparent increase in the
size of the contrast-enhancing lesion that does not reflect
tumour progression, but rather treatment-related reactive
changes. It is often claimed to be related to combined mod-
ality treatment of malignant gliomas [40], but can be seen
after radiotherapy alone. Its frequency and clinical signific-
ance are difficult to estimate since temozolomide is usually
continued in patients who are clinically stable or improved,
but whose MRI scans appear to indicate progressive dis-
ease. This practice is reasonable, but precludes differenti-
ation of pseudoprogression from delayed responses to te-
mozolomide.
The role of other imaging modalities, including single
photon emission-computed tomography (SPECT), positron
emission tomography (PET), MR spectroscopy and func-
tional MRI is currently being explored. In particular, amino
acid PET is increasingly being used to identify hot spots in-
dicative of malignant foci within extensive lesions and to
define target volumes for radiotherapy.
EEG has a limited role in monitoring symptomatic epilepsy
in brain tumour patients, but not to monitor disease pro-
gression. Serum biomarkers currently play no role in the
follow-up of malignant glioma patients.
Symptomatic treatment and
supportive care
Symptomatic treatment measures are of central importance
in the management of malignant glioma patients. Corticos-
teroids are very effective in controlling tumour-associated
brain oedema, but they are also a major source of reduced
quality of life in this patient population. Accordingly, they
should always be given at the lowest dose possible, and
every option to taper or discontinue steroids should be
used.
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Malignant glioma patients are at a high risk of throm-
boembolic complications, and pulmonary embolism is a
common non-tumour-related death. Therefore, prophylact-
ic heparin should be considered in patients at risk, and
secondary prophylaxis with either fractionated heparin or
coumarin is safe and effective and not associated with an
unacceptable risk of tumour bleeding [41].
Approximately 50% of malignant glioma patients will ex-
perience at least one epileptic seizure during the course
of their disease. Primary prophylaxis with anti-epileptic
drugs in patients without seizure history is not indicated,
but patients suffering seizures beyond the early postoper-
ative period may require anti-epileptic drugs for life [42].
Traditional agents like phenobarbitone, phenytoin or car-
mazepine have largely been replaced by newer drugs with
a superior safety, tolerability and interaction profile, not-
ably levetiracetam and lamotrigine. The prognostic impact
of the choice of anti-epileptic drug remains controversial.
Analysis of the EORTC NCIC trial database suggested
that valproid acid enhanced haematological toxicity, but
improved overall survival specifically in temozolomide-
treated patients [43]. It is tempting to speculate that the
histone deacetylase (HDAC) inhibitory activity of valproid
acid contributed to this effect. Phase II trials using more po-
tent HDAC inhibitors such as vorinostat are ongoing.
Given the overall improved outcome of malignant glioma
patients, the need for neurorehabilitative measures should
be constantly assessed. Finally, depression is a common,
probably under recognised and under-treated condition in
malignant glioma patients, and, as the disease evolves and
becomes dominant in the life of patients and their care-
givers, psychological and psycho-oncological support
should be offered to all patients and their relatives.
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